Could a Two-Drug HIV pill be enough for transgender women?
Disease control
Recruiting now
This study tests if switching to a two-drug combination (dolutegravir and lamivudine) can safely keep HIV under control in transgender women who are already on a stable three-drug regimen. About 50 participants will take the new pills for 48 weeks. The goal is to see if the simpl…
Phase: PHASE4 • Sponsor: UBATEC • Aim: Disease control
Last updated May 08, 2026 12:03 UTC